Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cancer Biol Ther. 2012 Jan 1;13(1):1-13. doi: 10.4161/cbt.13.1.18438.
Early stage endometrial cancer is generally curable. However, progress in the treatment of advanced and recurrent endometrial cancer has been limited. This has led to a shift from the use of traditional chemotherapeutic agents and radiotherapy regimens to the promising area of targeted therapy, given the large number of druggable molecular alterations found in endometrial cancer. To maximize the effects of directed targeted therapy, careful molecular characterization of the endometrial tumor is necessary. This represents an important difference in the use of targeted therapy vs. traditional chemotherapy or radiation treatment. This review will discuss relevant pathways to target in endometrial cancer as well as the challenges that arise during development of a personalized oncology approach.
早期子宫内膜癌通常是可治愈的。然而，晚期和复发性子宫内膜癌的治疗进展有限。鉴于在子宫内膜癌中发现了大量可用药的分子改变，这促使人们从传统的化疗药物和放疗方案转向有前途的靶向治疗领域。为了最大限度地提高靶向治疗的效果，有必要对子宫内膜肿瘤进行仔细的分子特征分析。这是靶向治疗与传统化疗或放疗相比的一个重要区别。本文将讨论在子宫内膜癌中靶向相关途径以及在制定个性化肿瘤学方法时出现的挑战。
